• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Qure.ai to Debut Multimodality AI Platform for Lung Cancer Imaging at ASCO 2024

News
Article

In addition to detecting missed lung nodules on X-rays, the AI-powered Qure.ai lung cancer continuum platform reportedly automates lung nodule measurement on CT scans and facilitates multimodality reporting.

Offering multimodality potential in detecting, monitoring, and reporting of lung cancer, Qure.ai will introduce an artificial intelligence (AI)-enabled lung cancer continuum platform at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Key attributes of the lung cancer continuum platform include AI-enabled lung nodule measurement and tracking of volumetric growth of disease, according to Qure.ai, the developer of the platform. The company said the lung cancer continuum platform enables monitoring of drug efficacy, provides triage prioritization, and facilitates multimodality reporting.

Qure.ai to Debut Multimodality AI Platform for Lung Cancer Imaging at ASCO 2024

Key attributes of the Qure. ai lung cancer continuum platform, slated to debut at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, include AI-enabled lung nodule detection, measurement and tracking of volumetric growth of lung disease, according to Qure.ai, the developer of the platform. (Image courtesy of Qure.ai.)

Qure.ai also emphasized the capability of the lung cancer continuum platform to improve early detection of lung cancer through detection of lung nodules missed on X-rays.

“Artificial intelligence for lung cancer powers early detection, not just as part of existing screening programs, but by finding small pulmonary nodules, often opportunistically, during general health-care imaging procedures,” noted Prashant Warier, the CEO and co-founder of Qure.ai. “This enables earlier identification and referral for imaging or treatment pathways. It also helps overcome the ongoing challenges of low lung cancer screening appointment uptake rates.”

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.